Shenzhen Gudeli takes 50.48% of Saizhuo Pharmaceutical via court auction
What's the deal? Shenzhen Gudeli New Materials Co., Ltd.Dealroom has a profile for this one. Try Dealroom → has become the controlling shareholder of Saizhuo PharmaceuticalDealroom has a profile for this one. Try Dealroom → (831312.NQ) after acquiring 53,000,000 shares — 50.48% of total equity — through an online judicial auction. Saizhuo disclosed the change on October 12, 2026, confirming that Li Chengjin is now the company's actual controller.
Why now? Gudeli won the shares on August 2, 2026. The Chengdu Intermediate People's Court issued an enforcement ruling on August 13, lifting Gudeli's stake from 0% to 50.48%, and the transfer was registered with the China Securities Depository and Clearing CorporationDealroom has a profile for this one. Try Dealroom → on October 8.
What's the endgame? Saizhuo operates in healthcare, mainly distributing pharmaceuticals. Gudeli says it plans to expand the company's marketing, with a focus on selling antibiotics in overseas markets, and to optimise its capital structure.
The numbers: Saizhuo reported first-half 2026 revenue of US$1.51M, down 43.82% year on year, and a net loss attributable to the parent of US$275K. Full-year 2025 revenue was US$4.95M, down 12.79%, with a net loss of US$1.38M. Cefixime dispersible tablets made up 94.01% of its main business in the first half of 2026.
The signal: A materials company taking majority control of a loss-making drug distributor through a judicial auction underlines how distressed-asset sales are reshaping China's small-cap pharma market — and how buyers from outside the sector are betting on export growth to turn the business around.
Read more: sohu.com
Image credit: Joe Gratz
